论文部分内容阅读
为探索晚期卵巢癌新的化疗方案以提高一线化疗疗效,德国Arbeitsgemeinschaft妇科肿瘤卵巢癌协作组1997年1～10月,对27例以前未曾治疗的晚期妇科肿瘤患者应用表阿霉素(E)、卡铂(Carbo)及紫杉醇(T)进行临床Ⅰ、Ⅱ期试验。一级剂量为E60mg/m~2年、T175mg/m~2、Carbo曲线下面积(AUC)5;二级剂重为E 75mg/m~2、T175mg/m~2、Carbo AUC5。一级剂量者E的剂量开始为60 mg/m~2,以后逐渐提高剂量15mg/m~2(即60,75及90mg/m~2)。三种药物均在第一天给药,21天重复。可评估26例
In order to explore a new chemotherapy regimen for advanced ovarian cancer to improve the efficacy of first-line chemotherapy, the Arbeitsgemeinschaft Gynecologic Oncology Ovarian Cancer Cooperative Group from January 1997 to October 1997 applied epirubicin (E) to 27 previously untreated patients with advanced gynecologic cancer, Carbo and paclitaxel (T) clinical stage Ⅰ, Ⅱ test. The first dose of E60mg / m ~ 2 years, T175mg / m ~ 2, Carbo curve under the area (AUC) 5; two doses of E 75mg / m ~ 2, T175mg / m ~ 2, Carbo AUC5. The first dose of E began to dose of 60 mg / m ~ 2, then gradually increase the dose 15mg / m ~ 2 (ie 60,75 and 90mg / m ~ 2). The three drugs were given on the first day and repeated on 21 days. 26 cases can be evaluated